PUBLIC COMPANY
save$SDGRSchrodinger, Inc.
$SDGR30.31-0.49%New York, NY, USupdated 14h ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Apr 17, 26option exerciseFarid Ramy · President & CEO74,527 sh
- Apr 17, 26option exerciseFarid Ramy · President & CEO43,000 sh
- Apr 17, 26option exerciseFarid Ramy · President & CEO74,527 sh
- Apr 17, 26option exerciseFarid Ramy · President & CEO43,000 sh
- Apr 16, 26option exerciseFarid Ramy · President & CEO43,000 sh
- Apr 16, 26option exerciseFarid Ramy · President & CEO43,000 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
News
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra useKaryopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…biopharma_dive · 22d ago
- Schrödinger births new immunology and inflammation biotech, Tectora TherapeuticsSchrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.fiercebiotech · 25d ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that